Company (Location)

Company (Location)

Value (M)

Type/Product Area

Terms/Details (Date)

D-Pharm Ltd. (Rehovot, Israel)

Jiangsu NHWA Pharmaceutical Co. Ltd. (China)

ND

Partnership to commercialize D-Pharm's DP-VPA therapy for Epilepsy in China

D-Pharm will receive up-front and developmental milestone payments, plus sales bonuses and royalties (6/1)

Ligand Pharmaceuticals Inc. (San Diego)

Merck & Co. Inc. (Whitehouse Station, N.J.)

ND

Captisol supply agreement for an undisclosed program

Ligand will supply clinical and commercial supplies of Captisol and, if the program is approved for commercialization, expects to deliver multiple metric tons annually (6/21)

Medivir AB (Huddinge, Sweden)

Daewoong Pharmaceutical Co. Ltd. (Seoul, South Korea)

ND

Agreement to distribute Xerclear, a cold sore treatment, in China and Hong Kong

Daewoong will carry out clinical studies and obtain regulatory approval for marketing and sales of the product in those territories; Medivir will be eligible for royalties (6/24)

Merck & Co. Inc. (Whitehouse Station, N.J.)

Roche AG (Basel, Switzerland)

ND

Nonexclusive deal for the global promotion of protease inhibitor Victrelis as part of a triple combination therapy regimen with peginterferon alfa and ribavirin

The firms previously disclosed an agreement to promote Victrelis in the U.S., where it gained marketing approval this year (7/21)

Victory Pharma Inc. (San Diego)

Shionogi Inc. (Florham Park, N.J.)

$127

Agreement for Shionogi to acquire all currently marketed products from Victory, including seven treatments for pain and two for infectious diseases

The FDA-approved products will be marketed by Shionogi's existing sales force; terms indicated a $118M cash payment at closing with up to $9M in additional milestone payments (7/19)

Wellstat Therapeutics Corp. (Gaithersburg, Md.)

BTG International Inc. (London)

ND

Deal for U.S. marketing rights for uridine triacetate to treat accidental overexposure to chemotherapy drug fluorouracil due to dosing errors or imparied clearance from the body

BTG gains rights in the U.S. for up to 10 years after approval, while Wellstat retains them outside the U.S. and for all other potential uses; Wellstat gets an up-front payment, milestone payments, transfer pricing payments based on manufacturing costs and a significant percentage of net sales (7/7)

Notes:

The date indicated refers to the BioWorld Today issue in which the news item can be found.

** Denotes the date the item ran in BioWorld International.

This chart may include collaborations between two pharmaceutical companies that involve a biotech product.